Novartis Recalls Diovan Blood Pressure Medication Due to Failed Dissolution Specifications

Novartis Pharmaceuticals Corporation has issued a nationwide recall for certain lots of its Diovan (valsartan) 160-milligram, 90-tablet bottles. The recall, reported on August 13, 2026, is due to 'failed dissolution specifications,' meaning the tablets did not meet the required standard for how quickly and how much of the active ingredient dissolved during testing. The FDA classified this as a Class II recall, indicating that use of the product may cause temporary or medically reversible health problems, with a remote risk of serious adverse consequences.